← Leaderboards
Martina Buck
University Of California San Diego
$5,094,327
Attributed
$8,434,702
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–24$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,434,702 · 11
By mechanism
R44$3,901,921 · 3
R01$1,552,937 · 1
R41$934,813 · 3
RC1$876,577 · 1
K01$674,780 · 1
K22$491,723 · 1
Top collaborators
- Mario Chojkier10 shared
- Michael Norman Krupp4 shared
Others in their field
Top investigators on “Phosphorylation”
- Paul S. Aisen · Cognition Therapeutics, Inc.$88,828,963
- Alan F Horwitz · University Of Virginia Charlottesville$38,916,638
- Tony R. Hunter · Salk Institute For Biological Studies$34,955,666
- Adam L Boxer · Mayo Clinic Rochester$31,930,809
- Keith A. Johnson · Banner Health$30,350,302
- Paul Greengard · Rockefeller University$28,632,392
Research focus
PhosphorylationLiverHepatocyteMedicalPeptidesHepatitis CPhosphotransferasesIn VitroHepatitis C VirusMolecularPathway InteractionsSignal TransductionPhysiologicalProteinsSiteFamilyCellsParticleInjuryInflammationApoptosisInfectionLeadTissues
Grant awards (26)
An Agnostic, Host-Direct Survival Cure MCM for Pulmonary Toxicants.$999,601
R44 · FY2024 · AI · contact PI
TREATMENT OF LUNG FIBROSIS : IND PHARMACOLOGY AND TOXICOLOGY$1,326,982
R44 · FY2020 · HL · contact PI
TREATMENT OF LIVER INJURY AND FIBROSIS: SAFETY PHARMACOLOGY AND TOXICOLOGY$1,136,111
R44 · FY2020 · DK
TREATMENT OF LUNG FIBROSIS : IND PHARMACOLOGY AND TOXICOLOGY$224,967
R44 · FY2019 · HL
TREATMENT OF LIVER INJURY AND FIBROSIS: SAFETY PHARMACOLOGY AND TOXICOLOGY$214,260
R44 · FY2019 · DK
Targeting C/EBP-beta Phosphorylation for the Treatment of Lung Fibrosis$316,111
R41 · FY2015 · HL
C/EBP-beta PEPTIDES FOR THE TREATMENT OF LUNG INJURY AND FIBROSIS$311,803
R41 · FY2014 · HL
Hepatitis C: E2 Molecular Mechanisms$290,882
R01 · FY2014 · DK · contact PI
C/EBP-beta PEPTIDES FOR THE TREATMENT OF LIVER INJURY AND FIBROSIS$306,899
R41 · FY2013 · DK
Hepatitis C: E2 Molecular Mechanisms$280,701
R01 · FY2013 · DK · contact PI
Hepatitis C: E2 Molecular Mechanisms$290,882
R01 · FY2012 · DK · contact PI
Hepatitis C: E2 Molecular Mechanisms$296,880
R01 · FY2011 · DK · contact PI
Hepatitis C: E2 Molecular Mechanisms$39,592
R01 · FY2011 · DK · contact PI
C/EBP beta Peptides for the Treatment of Hepatic Fibrosis$409,097
RC1 · FY2010 · DK · contact PI
Hepatitis C: E2 Molecular Mechanisms$354,000
R01 · FY2010 · DK · contact PI
HEPATOCELLULAR CARCINOMA AND HEPATITIS C: E2 MOLECULAR MECHANISMS$148,770
K22 · FY2010 · CA · contact PI
C/EBP beta Peptides for the Treatment of Hepatic Fibrosis$467,480
RC1 · FY2009 · DK · contact PI
HEPATOCELLULAR CARCINOMA AND HEPATITIS C: E2 MOLECULAR MECHANISMS$148,770
K22 · FY2009 · CA · contact PI
HEPATOCELLULAR CARCINOMA AND HEPATITIS C: E2 MOLECULAR MECHANISMS$45,413
K22 · FY2009 · CA · contact PI
HEPATOCELLULAR CARCINOMA AND HEPATITIS C: E2 MOLECULAR MECHANISMS$148,770
K22 · FY2008 · CA · contact PI
INFECTION AND REPLICATION OF NATURALLY OCCURRING HEPATITIS C VIRUS$1,951
P41 · FY2008 · RR · contact PI
HEPATIC CARCINOGENESIS: MOLECULAR MECHANISMS$148,770
K01 · FY2006 · CA · contact PI
HEPATIC CARCINOGENESIS: MOLECULAR MECHANISMS$148,770
K01 · FY2005 · CA
HEPATIC CARCINOGENESIS: MOLECULAR MECHANISMS$146,412
K01 · FY2004 · CA
HEPATIC CARCINOGENESIS: MOLECULAR MECHANISMS$116,721
K01 · FY2003 · CA
HEPATIC CARCINOGENESIS: MOLECULAR MECHANISMS$114,107
K01 · FY2002 · CA